Louise Damian, Vincent Langlois, Fabrice Jardin, Jean-Marc Kerleau, Maximilien Grall, Hervé Levesque, Ygal Benhamou, Gaëtan Sauvetre
{"title":"Predictors of progression to chronicity in newly diagnosed primary immune thrombocytopenia: a retrospective multicenter French study.","authors":"Louise Damian, Vincent Langlois, Fabrice Jardin, Jean-Marc Kerleau, Maximilien Grall, Hervé Levesque, Ygal Benhamou, Gaëtan Sauvetre","doi":"10.1080/17474086.2025.2495669","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The long-term outcome of primary immune thrombocytopenia (ITP) is unpredictable. Chronic ITP is common in adults, requiring second-line treatments with increased morbidity and mortality. Our study aimed to identify predictive factors of chronicity at the time of diagnosis in primary adult ITP.</p><p><strong>Research design and methods: </strong>This retrospective multicenter study included adult patients newly diagnosed with primary ITP. Patients with a normal platelet count and no ongoing medication twelve months after disease onset were categorized in the complete remission ITP group, otherwise in the chronic ITP group.</p><p><strong>Results: </strong>219 patients were included, 110 in the complete remission ITP group and 109 in the chronic ITP group. In multivariate analysis, predictive factors of progression to chronicity included the absence of an infectious event preceding ITP onset (p = 0.048), the absence of bleeding manifestations (p = 0.002) and a platelet count >10 x 109/L at disease onset (p = 0.02). A poor response to initial corticosteroid treatment was also associated with chronicity, including corticosteroid dependence (p<0.001) and corticosteroid resistance (p = 0.001).</p><p><strong>Conclusions: </strong>In this retrospective French cohort, predictors of chronicity in newly diagnosed primary adult ITP included the absence of preceding infectious event, platelet >10 x 109/L and absence of bleeding manifestations at onset.</p>","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"409-415"},"PeriodicalIF":2.3000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474086.2025.2495669","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The long-term outcome of primary immune thrombocytopenia (ITP) is unpredictable. Chronic ITP is common in adults, requiring second-line treatments with increased morbidity and mortality. Our study aimed to identify predictive factors of chronicity at the time of diagnosis in primary adult ITP.
Research design and methods: This retrospective multicenter study included adult patients newly diagnosed with primary ITP. Patients with a normal platelet count and no ongoing medication twelve months after disease onset were categorized in the complete remission ITP group, otherwise in the chronic ITP group.
Results: 219 patients were included, 110 in the complete remission ITP group and 109 in the chronic ITP group. In multivariate analysis, predictive factors of progression to chronicity included the absence of an infectious event preceding ITP onset (p = 0.048), the absence of bleeding manifestations (p = 0.002) and a platelet count >10 x 109/L at disease onset (p = 0.02). A poor response to initial corticosteroid treatment was also associated with chronicity, including corticosteroid dependence (p<0.001) and corticosteroid resistance (p = 0.001).
Conclusions: In this retrospective French cohort, predictors of chronicity in newly diagnosed primary adult ITP included the absence of preceding infectious event, platelet >10 x 109/L and absence of bleeding manifestations at onset.
期刊介绍:
Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.